HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   her2group (https://her2support.org/vbulletin/forumdisplay.php?f=28)
-   -   herceptin working or not? (https://her2support.org/vbulletin/showthread.php?t=33288)

mimiflower07 03-30-2008 10:45 AM

herceptin working or not?
 
how do we know if herceptin is working or not? Just wondering if i'm stage 2 and started herceptin in Feb, my next app with onc is May. Is there a marker that they can use or not really. I'm feeling some what insecure thinking that what if... question. I really hate this rollercoaster!
thanks for listening
suzanne

juanita 03-30-2008 01:10 PM

Some oncs use tumor markers, some don't. There's a poll about it. My markers were higher while I was doing chemo and herceptin, then went down after I was done.

Lani 03-30-2008 02:22 PM

the following article is based on those who are Stage IV, but research is ongoing
 
to see if a similar response is indicative of efficacy in the adjuvant setting

A paper whose abstract I previously posted seems to show similar applicability of this in the neoadjuvant setting--

It might have been helpful to have a serum her2 ECD ELISA test prior to starting herceptin and then a retest around 2-3 weeks later to see if
the serum concentration of the shed extracellular domaiin decreased.

This is still being worked out and is far from accepted practice.

Just letting you know where the research may be leading.

: Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8. Links

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. festeva@mdanderson.org
INTRODUCTION: The purpose of this retrospective study was to determine the clinical utility of serum HER2/neu in monitoring metastatic breast cancer patients undergoing trastuzumab-based therapy and to compare these results with those obtained using cancer antigen (CA) 15-3. We also sought to determine whether early changes in serum HER2/neu concentrations could be a predictor of progression-free survival. METHODS: Sera were obtained retrospectively from 103 women at four medical institutions. Patients eligible for participation were women with metastatic breast cancer who had HER2/neu tissue overexpression and were scheduled to be treated with trastuzumab with or without additional therapies as per the established practices of the treating physicians. A baseline serum sample for each patient was taken before trastuzumab-based therapy was started. Patients were subsequently monitored over 12 to 20 months and serum samples were taken at the time of clinical assessment and tested with Bayer's HER2/neu and CA15-3 assays. RESULTS: Concordance between clinical status in patients undergoing trastuzumab-based treatment and HER2/neu and CA15-3 used as single tests was 0.793 and 0.627, respectively, and increased to 0.829 when the tests were used in combination. Progression-free survival times did not differ significantly in patients with elevated baseline HER2/neu concentrations (> or = 15 ng/mL) and those with normal concentrations (<15 ng/mL). However, progression-free survival differed significantly (P = 0.043) according to whether the patient's HER2/neu concentration at 2 to 4 weeks after the start of therapy was >77% or < or = 77% of her baseline concentration. The median progression-free survival times for these two groups were 217 and 587 days, respectively. A similar trend was observed for a subcohort of patients treated specifically with a combination of trastuzumab and taxane. CONCLUSION: These findings indicate that serum HER2/neu testing is clinically valuable in monitoring metastatic breast cancer patients undergoing trastuzumab-based treatment and provides additional value over the commonly used CA15-3 test. The percentage of baseline HER2/neu concentrations in the early weeks after the start of therapy may be an early predictor of progression-free-survival.
PMID: 15987448 [PubMed - indexed for MEDLINE]

sassy 03-30-2008 03:37 PM

Suzanne,

Just wanted to let you know that you are not alone in feeling anxiety, and as if you are on a roller coaster. Hang in there. The farther out from dx you get, your anxiety will probably lessen and you will find that you are able to have longer periods of time where BC is not in the front of your mind.

Others more knowledgable than I will help you with the technical answers. Just know that we are all here any time you need us!

mimiflower07 03-30-2008 05:41 PM

thanks to you all for sharing with me...think i was having a freak out night.
I feel like we are so busy going thru treatment that after the dust settles the fear arrives. For me its always at night!(for most of us)
anyway thankyou!
suzanne

capj_823 03-31-2008 02:07 PM

Is Herceptin working??
 
It will be 1 year in April since I completed Herceptin. I always ask my oncologist if it is working or not . . . she sort of brushes me off! But I really don't worry about it too much any more. I watch for lumps . . . and when I visit my oncologist in May -- I will bug her about it again. But your anxiety will lesson.


All times are GMT -7. The time now is 08:52 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021